IL99180A - Dosage forms for controlled release that can be biodegradable - Google Patents

Dosage forms for controlled release that can be biodegradable

Info

Publication number
IL99180A
IL99180A IL99180A IL9918091A IL99180A IL 99180 A IL99180 A IL 99180A IL 99180 A IL99180 A IL 99180A IL 9918091 A IL9918091 A IL 9918091A IL 99180 A IL99180 A IL 99180A
Authority
IL
Israel
Prior art keywords
polymer
active agent
pharmacologically active
dosage form
ivermectin
Prior art date
Application number
IL99180A
Other languages
English (en)
Hebrew (he)
Other versions
IL99180A0 (en
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL99180A0 publication Critical patent/IL99180A0/xx
Publication of IL99180A publication Critical patent/IL99180A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL99180A 1990-08-22 1991-08-14 Dosage forms for controlled release that can be biodegradable IL99180A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57074290A 1990-08-22 1990-08-22

Publications (2)

Publication Number Publication Date
IL99180A0 IL99180A0 (en) 1992-07-15
IL99180A true IL99180A (en) 1998-01-04

Family

ID=24280874

Family Applications (1)

Application Number Title Priority Date Filing Date
IL99180A IL99180A (en) 1990-08-22 1991-08-14 Dosage forms for controlled release that can be biodegradable

Country Status (13)

Country Link
US (1) US5837228A (pt)
EP (1) EP0473223B1 (pt)
JP (1) JP2588328B2 (pt)
AT (1) ATE122230T1 (pt)
AU (1) AU645594B2 (pt)
CA (1) CA2049668C (pt)
DE (1) DE69109581T2 (pt)
DK (1) DK0473223T3 (pt)
ES (1) ES2072530T3 (pt)
IE (1) IE67141B1 (pt)
IL (1) IL99180A (pt)
NZ (1) NZ239370A (pt)
PT (1) PT98708B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5211951A (en) * 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
ATE209907T1 (de) * 1994-04-08 2001-12-15 Atrix Lab Inc Flüssige mittel zur wirkstoffabgabe
WO1999015166A1 (en) * 1997-09-23 1999-04-01 Pfizer Limited Parasiticidal formulations
US6524602B1 (en) * 1998-10-13 2003-02-25 Craig G. Burkhart Polymer delivery system in treatments for parasitic skin diseases
HUP0200374A2 (en) * 1999-03-11 2002-06-29 Nestle Sa Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001288829A1 (en) 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
WO2002067895A2 (en) * 2000-11-16 2002-09-06 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
AUPR602401A0 (en) 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR602501A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release pharmaceutical composition
AUPR610501A0 (en) * 2001-07-04 2001-07-26 Smart Drug Systems Inc Treatment of parasitic disease
US6627613B2 (en) 2001-07-23 2003-09-30 Michael A. Strobel Application of water and organic solvent soluble ivermectin for topical and oral use
US20050009762A1 (en) 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
US20040142902A1 (en) * 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7288609B1 (en) * 2003-03-04 2007-10-30 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices based on poly (orthoesters)
WO2004100926A2 (en) * 2003-05-13 2004-11-25 Medtronic, Inc. Delivery of agents using hydrolyzable leaving groups
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US7875697B2 (en) 2006-06-29 2011-01-25 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
BRPI0922189A2 (pt) * 2008-12-11 2018-10-23 A P Pharma Inc "métodos para aumentar a estabilidade de poliortoésteres e suas formulações".
CA2806153C (en) 2010-07-30 2021-01-12 Ceva Sante Animale Compositions for controlling heartworm infestation
US9393193B2 (en) * 2010-07-30 2016-07-19 Ceva Santa Animale Compositions for controlling heartworm infestation
BR112014013371B1 (pt) 2011-12-02 2020-04-07 Merial Ltd formulações de moxidectina injetável de ação prolongada e novas formas de cristal de moxidectina
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation REDUCED IMPURITY EXTENDED-RELEASE DRUG DELIVERY SYSTEMS AND METHODS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4150108A (en) * 1975-12-29 1979-04-17 Graham Neil B Injectable medicinal compositions
DE2861226D1 (en) * 1977-06-28 1981-12-10 Univ Strathclyde A pharmaceutical composition for tropical diseases
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4636387A (en) * 1982-06-21 1987-01-13 Research Corporation Anesthetic polyorganophosphazenes
US4765973A (en) * 1984-06-06 1988-08-23 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4639366A (en) * 1984-06-06 1987-01-27 Merck & Co., Inc. Polymers containing pendant acid functionalities and labile backbone bonds
US4764764A (en) * 1984-11-27 1988-08-16 Honeywell Inc. Write-protect apparatus for bit mapped memory
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
US4764364A (en) * 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
AU2902289A (en) * 1987-12-08 1989-07-05 Mark Chasin Method of forming bioerodible implants for improved controlled drug release

Also Published As

Publication number Publication date
PT98708A (pt) 1992-08-31
DK0473223T3 (da) 1995-07-10
IE912965A1 (en) 1992-02-26
PT98708B (pt) 1999-01-29
EP0473223A1 (en) 1992-03-04
IE67141B1 (en) 1996-03-06
CA2049668C (en) 2002-11-12
CA2049668A1 (en) 1992-02-23
DE69109581D1 (de) 1995-06-14
NZ239370A (en) 1994-04-27
ES2072530T3 (es) 1995-07-16
ATE122230T1 (de) 1995-05-15
EP0473223B1 (en) 1995-05-10
US5837228A (en) 1998-11-17
JP2588328B2 (ja) 1997-03-05
JPH04230621A (ja) 1992-08-19
AU8267891A (en) 1992-02-27
DE69109581T2 (de) 1996-01-18
AU645594B2 (en) 1994-01-20
IL99180A0 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
US5837228A (en) Bioerodible implants
US5211951A (en) Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
Kitchell et al. [32] Poly (lactic/glycolic acid) biodegradable drug—polymer matrix systems
EP0635272B1 (en) Liquid absorbable copolymers for parenteral applications
US6984393B2 (en) Biodegradable elastomer and method of preparing same
US4882168A (en) Polyesters containing alkylene oxide blocks as drug delivery systems
US4130639A (en) Absorbable pharmaceutical compositions based on isomorphic copolyoxalates
WO1993003739A1 (en) Biocompatible and biodegradable poly(phosphoester-urethanes)
EP0258780A2 (en) Polyesters containing alkylene oxide blocks as drug delivery systems
HU186904B (en) Process for producing retarde pharmaceutical compositions
KR20100120243A (ko) 약물 전달 장치를 형성하는 공정
Heller et al. Use of poly (ortho esters) for the controlled release of 5-fluorouracyl and a LHRH analogue
AU2014203350B2 (en) Subcutaneous implants containing a degradation-resistant polylactide polymer and a lh-rh analogue
Bruining et al. New biodegradable networks of poly (N‐vinylpyrrolidinone) designed for controlled nonburst degradation in the vitreous body
CA2108680A1 (en) Improved retard systems for the sustained release of medicinal and/or biological valuable materials from a depot carrier material
EP1458352A1 (en) Solid dose micro implant
US5254345A (en) Poly(orthocarbonate acetal) bioerodible polymers
WO1999051201A1 (en) Sustained release formulation
KR20050007377A (ko) 약물 전달 장치를 형성하는 공정
AU3176999A (en) Sustained release formulation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees